Abstract
Myocardial contractility was studied in vitro in response to treatment with class III antiarrhythmic drug Nibentan. The contractile response to Nibentan in increasing concentrations of 1.66, 2.5, and 3.5 mM was estimated on strips of animal myocardium and human right atrial auricle.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
K. Yu. Bogdanov, T. M. Vinogradova, and L. V. Rozenshtraukh, Kardiologiya, 37, No. 4, 28–33 (1997).
L. V. Rozenshtraukh, E. P. Anyukhovskii, G. G. Beloshapko, et al., Ibid., 35, No. 5, 25–36 (1995).
V. V. Fedorov, O. F. Sharifov, L. V. Rozenshtraukh, et al., Ibid., 39, No. 3, 45–57 (1999).
V. V. Fedorov, O. F. Sharifov, L. V. Rozenshtraukh, et al., Ibid., 40, No. 2, 37–47 (2000).
P. Dorian, J. Cardiovasc. Pharmacol. Ther., 8,Suppl. 1, S27–S31 (2003).
S. Nattel, T. Hadjis, and M. Talajic, Drugs, 48, 345–371 (1994).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 141, No. 1, pp. 89–91, January, 2006
Rights and permissions
About this article
Cite this article
Latfullin, I.A., Gaifullina, R.F., Dzhordzhikiya, R.K. et al. Myocardial contractility after in Vitro treatment with class III antiarrhythmic drug Nibentan. Bull Exp Biol Med 141, 81–83 (2006). https://doi.org/10.1007/s10517-006-0099-y
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10517-006-0099-y